Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer (NCT02947685)
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to demonstrate that the combination of palbociclib with anti-HER2 therapy plus endocrine therapy is superior to anti-HER2-based therapy plus endocrine therapy alone in improving the outcomes of subjects with hormone receptor-positive, HER2+ metastatic breast cancer.
Who can join: Review the eligibility criteria below.
Location: UCSF — San Francisco, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (106 Sites)
Showing the first 25 of 106 sites.
- UCSF — San Francisco, California
- Georgetown University Medical Center — Washington D.C., District of Columbia
- Baycare Healthcare (Morton Plant Mease) — Clearwater, Florida
- Memorial Healthcare System — Hollywood, Florida
- University of Miami — Miami, Florida
- Florida Hospital — Orlando, Florida
- Emory University — Atlanta, Georgia
- University of Illinois at Chicago — Chicago, Illinois
- Ingalls Memorial Hospital — Harvey, Illinois
- Cancer Center of Kansas — Wichita, Kansas
- Ochsner Medical Center Jefferson — New Orleans, Louisiana
- New England Cancer Specialists — Scarborough, Maine
- University of Maryland - Greenebaum Comprehensive Cancer Center — Baltimore, Maryland
- Johns Hopkins University/Sidney Kimmel Cancer Center — Baltimore, Maryland
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Lowell General Hospital — Lowell, Massachusetts
- Michigan Cancer Research Consortium (St. Joseph Mercy Hospital — Ann Arbor, Michigan
- West Michigan Cancer Center — Grand Rapids, Michigan
- Metro-Minnesota NCI Community Oncology Research Program — Minneapolis, Minnesota
- Mayo Clinic, Rochester, MN — Rochester, Minnesota
- Washington University School of Medicine — St Louis, Missouri
- Nebraska Methodist Hospital — Omaha, Nebraska
- University of Nebraska Medical Center — Omaha, Nebraska
- Hackensack Medical Center — Hackensack, New Jersey
- The Valley Hospital, Okonite Research Center — Paramus, New Jersey
📞 Contact the Study Coordinator
Phone: (877) 827-3222
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in HER-2 Positive Breast Cancer
- T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA — Boston, Massachusetts
Explore by condition: All HER-2 Positive Breast Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.